| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1027532239 |
| P356 | DOI | 10.2165/00002018-200124110-00002 |
| P3181 | OpenCitations bibliographic resource ID | 344182 |
| P698 | PubMed publication ID | 11665868 |
| P2093 | author name string | S Fiorucci | |
| A Morelli | |||
| E Antonelli | |||
| J L Burgaud | |||
| P2860 | cites work | The L-arginine-nitric oxide pathway | Q24304874 |
| Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs | Q24670111 | ||
| Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention | Q28181996 | ||
| NO-releasing NSAIDs are caspase inhibitors | Q28182519 | ||
| Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat | Q28244187 | ||
| Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor | Q28299224 | ||
| Nitric oxide and bone | Q28343869 | ||
| Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity | Q28344534 | ||
| A comparison of the effect of nitroparacetamol and paracetamol on liver injury | Q28345793 | ||
| Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs | Q29617192 | ||
| Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide | Q29619956 | ||
| Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs--emerging protective evidence? | Q33722492 | ||
| S-Nitrosothiols: a class of nitric oxide-donor drugs | Q33898909 | ||
| From bench to clinic with apoptosis-based therapeutic agents | Q34068970 | ||
| Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis | Q37363098 | ||
| Aspirin use and potential mechanisms for colorectal cancer prevention | Q37372265 | ||
| Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine | Q39140610 | ||
| The nitric oxide synthase family of proteins | Q40387673 | ||
| The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage--potential for development of gastrointestinal tract safe NSAIDs | Q40516972 | ||
| Clinical pharmacology of organic nitrates | Q40846555 | ||
| NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. | Q40858702 | ||
| A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group | Q41692489 | ||
| NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis | Q41857575 | ||
| Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons | Q42491893 | ||
| Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. | Q42542940 | ||
| Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative | Q42930380 | ||
| Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method | Q47337867 | ||
| Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma | Q47973070 | ||
| Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. | Q48285765 | ||
| Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester | Q50143315 | ||
| The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. | Q50534671 | ||
| The effects of a novel NSAID on chronic neuroinflammation are age dependent. | Q52172748 | ||
| Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. | Q53711537 | ||
| Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. | Q55066553 | ||
| NO-aspirin protects from T cell–mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines | Q58855408 | ||
| NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2 | Q60691062 | ||
| A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats | Q60695447 | ||
| A diclofenac derivative without ulcerogenic properties | Q60695451 | ||
| Inducible cyclooxygenase may have anti-inflammatory properties | Q61053473 | ||
| Nonsteroidal anti-inflammatory drug gastropathy | Q71523193 | ||
| NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects | Q73094778 | ||
| IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs | Q73112975 | ||
| Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs | Q73126827 | ||
| Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats | Q74307016 | ||
| Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding | Q74339271 | ||
| Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney | Q74408890 | ||
| Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin | Q74761398 | ||
| Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats | Q77374986 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 801-11 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Nitric oxide-releasing NSAIDs: a review of their current status | |
| P478 | volume | 24 |
| Q85068545 | A Double-Blind Controlled Trial of a Single Dose Naproxen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain |
| Q36050690 | A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations. |
| Q35555299 | A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis |
| Q113758063 | Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects |
| Q38014563 | Application of nitric oxide in drug discovery and development |
| Q39608385 | Aspirin regulates SNARE protein expression and phagocytosis in dendritic cells |
| Q36065254 | Assessing the negative impact of phenyl alkanoic acid derivative, a frequently prescribed drug for the suppression of pain and inflammation, on the differentiation and proliferation of chondrocytes |
| Q39382907 | COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. |
| Q92945552 | Carboranyl Analogues of Ketoprofen with Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines |
| Q90372572 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells |
| Q45236403 | Celecoxib inhibits ureteral contractility and prostanoid release |
| Q74069835 | Current awareness in pharmacoepidemiology and drug safety |
| Q43263866 | Cyclo-oxygenase-2 inhibition and exacerbation of myocardial dysfunction--protection with nitric oxide? |
| Q35196930 | Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis |
| Q36056243 | Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. |
| Q45283792 | Do selective cyclo-oxygenase-2 inhibitors have a future? |
| Q36066043 | Emerging analgesics in cancer pain management |
| Q58236625 | Gastroprotective Effects of L-Lysine Salification of Ketoprofen in Ethanol-Injured Gastric Mucosa |
| Q28196651 | NO-aspirin: mechanism of action and gastrointestinal safety |
| Q36951251 | Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics |
| Q43056088 | Oral bioavailability, efficacy and gastric tolerability of P2026, a novel nitric oxide-releasing diclofenac in rat. |
| Q28193422 | Potential cardioprotective actions of no-releasing aspirin |
| Q35097371 | Radical causes of cancer. |
| Q48322565 | The Native Fruit Geoffroea decorticans from Arid Northern Chile: Phenolic Composition, Antioxidant Activities and In Vitro Inhibition of Pro-Inflammatory and Metabolic Syndrome-Associated Enzymes. |
| Q90291267 | Three-Dimensional Renal Organoids from Whole Kidney Cells: Generation, Optimization, and Potential Application in Nephrotoxicology In Vitro |
| Q80562185 | [Management of the digestive risk in patients treated with NSAIDs. Synthesis and perspectives] |
Search more.